The Cancer of the Pancreas Screening-5 CAPS5)Study (CAPS5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02000089

Recruitment Status : Recruiting

First Posted : December 3, 2013

Last Update Posted : November 24, 2020

See Contacts and Locations

Sponsor:

Collaborators:

ChiRhoClin, Inc.

National Cancer Institute (NCI)

Information provided by (Responsible Party):

Johns Hopkins University

Study Description

Brief Summary:

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Condition or disease	Intervention/treatment
Pancreas Cancer Peutz-Jeghers Syndrome (PJS) Gene Mutation Germline Mutation Carrier Lynch Syndrome	Drug: Human synthetic secretin

Detailed Description:

The Sub Investigator at each site will be responsible for internal monitoring at their site. The site sub Investigator and study team will report any serious adverse events to Principal Investigator and annually report adverse events.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	3000 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	The Cancer of the Pancreas Screening-5 CAPS5)Study
Study Start Date :	January 2014
Estimated Primary Completion Date :	October 2024
Estimated Study Completion Date :	December 2025

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Peutz-Jeghers syndrome Lynch syndrome

MedlinePlus related topics: Pancreatic Cancer

Drug Information available for: Pancreatin Pancrelipase Secretin human

Genetic and Rare Diseases Information Center resources: Pancreatic Cancer Hereditary Pancreatitis Ataxia Telangiectasia Peutz-Jeghers Syndrome

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
Familial pancreas cancer relatives High Risk Group 2 (familial pancreatic cancer relatives): > 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and have a first-degree relationship with at least one of the relatives with pancreatic cancer. If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Group 1 germline mutation carrier High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher): > 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed BRCA2, or PALB2 mutation, and there is 1 or more pancreatic cancer diagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened. The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), age 40 years or older, regardless of family history of pancreas cancer.	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Group 2 germline mutation carrier High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%): > 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Hereditary pancreatitis High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Peutz-Jeghers Syndrome At least 30 years old, and at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or, known STK11 gene mutation carrier	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Negative control are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Chronic Pancreatitis are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and, have no clinical or radiologic suspicion of pancreatic cancer	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Pancreas cancer a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
Pancreas cyst, IPMN evaluation are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).	Drug: Human synthetic secretin I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts

Outcome Measures

Primary Outcome Measures :

Evaluate pancreatic juice for early cancer markers. [ Time Frame: 10 years ]
Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls.

Secondary Outcome Measures :

Compare pancreas juice with pancreas cyst fluid [ Time Frame: 10 years ]
Aim #2: To compare the prevalence of pancreatic fluid mutations and circulating pancreatic epithelial cells among a prospective cohort of individuals with sporadic pancreatic cysts undergoing pancreatic surveillance.

Other Outcome Measures:

Time disease progression and prevalence [ Time Frame: 10 years ]
Aim #3: To determine the prevalence of pancreatic lesions, pancreatic fluid mutations and circulating pancreatic epithelial cells among a large cohort of high-risk individuals undergoing pancreatic screening and surveillance of a new cohort in which screening is begun at age >55.

Biospecimen Retention: Samples With DNA

approximately 40 ml of blood approximately 5-20 ml duodenal fluid approximately 5-20 ml pancreas juice (optional) approximately 10 ml saliva (optional) pancreas cyst fluid (if available)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Individuals at elevated risk for developing pancreas cancer

Criteria

Inclusion Criteria:

Hereditary Pancreatitis or
Peutz-Jeghers Syndrome or
Strong family history of pancreas cancer on one side of the family tree or
Confirmed germline mutation carrier (BRCA2, FAMMM, PALB2, BRCA1, HNPCC, PRSS1/2, or CTRC
Endoscopic evaluation of pancreas scheduled

Exclusion Criteria:

Medical comorbidities or coagulopathy that contraindicate endoscopy
Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis
Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope
Poor performance status
Inability to provide informed consent
Pregnancy.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02000089

Contacts

Layout table for location contacts

Contact: Hilary Cosby, RN		hcosby1@jhmi.edu

Locations

Layout table for location information

United States, Connecticut
Yale University	Recruiting
New Haven, Connecticut, United States, 06520
Contact: Scott Merenda, BSN 203-785-7019 scott.merenda@yale.edu
Contact: James Farrell, MD james.j.farrell@yale.edu
Sub-Investigator: James Farrell, MD
United States, Maryland
Johns Hopkins Hospital	Recruiting
Baltimore, Maryland, United States, 21287
Contact: Hilary Cosby, RN, CGRN 410-502-2893 hcosby1@jhmi.edu
Principal Investigator: Michael Goggins, MD
United States, Massachusetts
Dana Farber Cancer Center, Harvard University	Recruiting
Boston, Massachusetts, United States, 02215
Contact: Brigette Rankin 617-632-4788 BrigetteE_Rankin@DFCI.HARVARD.EDU
Contact: Chinedu Ukaegbu chinedu_ukaegbu@dfci.harvard.edu
Sub-Investigator: Sapna Syngal, MD
United States, Michigan
University of Michigan	Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Erika Koeppe, MS 734-998-1274 eskoeppe@med.umich.edu
Sub-Investigator: Elena Stoffel, MD
United States, New York
Columbia University Medical Center	Recruiting
New York, New York, United States, 10032
Contact: Tanjina Razzaque tr2432@cumc.columbia.edu
Sub-Investigator: Fay Kastrinos, MD
United States, Ohio
Case Comprehensive Cancer Center, Case Western Medical Reserve	Recruiting
Cleveland, Ohio, United States, 44106
Contact: Nancy Furrey, RN 216-844-7314 nancy.furey@uhhospitals.org
Sub-Investigator: Amitabh Chak, MD
United States, Pennsylvania
University of Pennsylvania	Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Maureen DeMarshall, RN 215-349-8546 demarshm@mail.med.upenn.edu
Sub-Investigator: Bryson Katona, MD
University of Pittsburgh	Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Beth Dudley dudleyre@mail.magee.edu
Contact: Randall Brand, MD brandre@upmc.edu
Sub-Investigator: Randy Brand, MD

Sponsors and Collaborators

Johns Hopkins University

ChiRhoClin, Inc.

National Cancer Institute (NCI)

Investigators

Layout table for investigator information

Principal Investigator:	Michael Goggins, MD	Johns Hopkins University

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kohi S, Macgregor-Das A, Dbouk M, Yoshida T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2020 Nov 5. pii: S1542-3565(20)31519-6. doi: 10.1016/j.cgh.2020.11.006. [Epub ahead of print]

Abe T, Koi C, Kohi S, Song KB, Tamura K, Macgregor-Das A, Kitaoka N, Chuidian M, Ford M, Dbouk M, Borges M, He J, Burkhart R, Wolfgang CL, Klein AP, Eshleman JR, Hruban RH, Canto MI, Goggins M. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2020 May;18(5):1161-1169.e5. doi: 10.1016/j.cgh.2019.10.036. Epub 2019 Oct 30.

Canto MI, Kerdsirichairat T, Yeo CJ, Hruban RH, Shin EJ, Almario JA, Blackford A, Ford M, Klein AP, Javed AA, Lennon AM, Zaheer A, Kamel IR, Fishman EK, Burkhart R, He J, Makary M, Weiss MJ, Schulick RD, Goggins MG, Wolfgang CL. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. J Gastrointest Surg. 2020 May;24(5):1101-1110. doi: 10.1007/s11605-019-04230-z. Epub 2019 Jun 13.

Layout table for additonal information

Responsible Party:	Johns Hopkins University
ClinicalTrials.gov Identifier:	NCT02000089
Other Study ID Numbers:	NA_00087754 1U01CA210170-01 ( U.S. NIH Grant/Contract )
First Posted:	December 3, 2013 Key Record Dates
Last Update Posted:	November 24, 2020
Last Verified:	November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Johns Hopkins University:


familial pancreas cancer (Peutz-Jeghers Syndrome) PJS Breast cancer (BRCA) 2 Partner and Locator of BRCA2 (PALB2) Familial Atypical Multiple Mole- Melanoma (FAMMM) p16 Breast Cancer (BRCA)1	(hereditary non-polyposis colorectal cancer or Lynch syndrome) HNPCC Lynch Syndrome hereditary pancreatitis Protease Serine (PRSS) Chymotrypsin C (CTRC) Ataxia Telangiectasia Mutated(ATM)

Additional relevant MeSH terms:

Layout table for MeSH terms

Pancreatic Neoplasms Colorectal Neoplasms, Hereditary Nonpolyposis Peutz-Jeghers Syndrome Syndrome Disease Pathologic Processes Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Colorectal Neoplasms Intestinal Neoplasms	Gastrointestinal Neoplasms Neoplastic Syndromes, Hereditary Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Genetic Diseases, Inborn DNA Repair-Deficiency Disorders Metabolic Diseases Intestinal Polyposis Lentigo Melanosis Hyperpigmentation Pigmentation Disorders Skin Diseases Secretin

To Top